These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 28290972)

  • 1. Malignant Hyperthermia Susceptibility and Fitness for Duty.
    Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
    Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
    Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
    Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis.
    O'Flynn RP; Shutack JG; Rosenberg H; Fletcher JE
    Anesthesiology; 1994 Jun; 80(6):1228-33. PubMed ID: 8010468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multigenerational Brazilian family with malignant hyperthermia and a novel mutation in the RYR1 gene.
    Matos AR; Sambuughin N; Rumjanek FD; Amoedo ND; Cunha LB; Zapata-Sudo G; Sudo RT
    Braz J Med Biol Res; 2009 Dec; 42(12):1218-24. PubMed ID: 19918671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant hyperthermia testing in probands without adverse anesthetic reaction.
    Timmins MA; Rosenberg H; Larach MG; Sterling C; Kraeva N; Riazi S
    Anesthesiology; 2015 Sep; 123(3):548-56. PubMed ID: 26068069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant hyperthermia.
    Rosenberg H; Davis M; James D; Pollock N; Stowell K
    Orphanet J Rare Dis; 2007 Apr; 2():21. PubMed ID: 17456235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
    Allen GC; Larach MG; Kunselman AR
    Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of caffeine-halothane contracture test in the diagnosis of malignant hyperthermia].
    Wang YL; Guo XY; Xu ZH; Huang YG; Luo AL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Apr; 30(2):182-6. PubMed ID: 18505122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
    Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
    Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current status of malignant hyperthermia.
    Yang L; Tautz T; Zhang S; Fomina A; Liu H
    J Biomed Res; 2019 May; 34(2):75-85. PubMed ID: 32305961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant hyperthermia: clinical and molecular aspects.
    Correia AC; Silva PC; da Silva BA
    Rev Bras Anestesiol; 2012; 62(6):820-37. PubMed ID: 23176990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant hyperthermia: update on susceptibility testing.
    Litman RS; Rosenberg H
    JAMA; 2005 Jun; 293(23):2918-24. PubMed ID: 15956637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility.
    Ibarra Moreno CA; Kraeva N; Zvaritch E; Figueroa L; Rios E; Biesecker L; Van Petegem F; Hopkins PM; Riazi S
    Br J Anaesth; 2020 Dec; 125(6):995-1001. PubMed ID: 32861507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study.
    Klingler W; Heiderich S; Girard T; Gravino E; Heffron JJ; Johannsen S; Jurkat-Rott K; Rüffert H; Schuster F; Snoeck M; Sorrentino V; Tegazzin V; Lehmann-Horn F
    Orphanet J Rare Dis; 2014 Jan; 9():8. PubMed ID: 24433488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant hyperthermia: current perspectives.
    Felice-Johnson J; Sudds T; Bennett G
    Am J Hosp Pharm; 1981 May; 38(5):646-51. PubMed ID: 7282692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant hyperthermia.
    Ali SZ; Taguchi A; Rosenberg H
    Best Pract Res Clin Anaesthesiol; 2003 Dec; 17(4):519-33. PubMed ID: 14661655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and diagnosis for Chinese cases with malignant hyperthermia: a case cluster from 2005 to 2007.
    Wang YL; Luo AL; Tan G; Cui XL; Guo XY
    Chin Med J (Engl); 2010 May; 123(10):1241-5. PubMed ID: 20529573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Malignant Hyperthermia - Update on Pathophysiology, Diagnostics and Treatment].
    Johannsen S; Schuster F
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2019 Sep; 54(9):527-537. PubMed ID: 31525786
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.